Table III.
Correlations between EZH2/HDAC1/2 expression and the clinicopathological characteristics in PTCL.
| EZH2 expression | HDAC1 expression | HDAC2 expression | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Characteristic | High | Low | P-value | High | Low | P-value | High | Low | P-value |
| Sex | |||||||||
| Male | 30 (58.8) | 21 (41.2) | 0.158 | 31 (60.8) | 20 (39.2) | 0.964 | 24 (47.1) | 27 (52.9) | 0.016b |
| Female | 23 (74.2) | 8 (25.8) | 19 (61.3) | 12 (38.7) | 23 (74.2) | 8 (25.8) | |||
| Age, years | |||||||||
| ≤60 | 32 (65.3) | 17 (34.7) | 0.877 | 34 (69.4) | 15 (30.6) | 0.057 | 30 (61.2) | 19 (38.8) | 0.383 |
| >60 | 21 (63.6) | 12 (36.4) | 16 (48.5) | 17 (51.5) | 17 (51.5) | 16 (48.5) | |||
| B-symptoms | |||||||||
| Present | 39 (73.6) | 14 (26.4) | 0.022b | 36 (67.9) | 17 (32.1) | 0.081 | 31 (58.5) | 22 (41.5) | 0.771 |
| Absent | 14 (48.3) | 15 (51.7) | 14 (48.3) | 15 (51.7) | 16 (55.2) | 13 (44.8) | |||
| Marrow involvement | |||||||||
| Present | 18 (78.3) | 5 (21.7) | 0.107 | 16 (69.6) | 7 (30.4) | 0.319 | 17 (85.0) | 3 (15.0) | 0.007 |
| Absent | 35 (59.3) | 24 (40.7) | 34 (57.6) | 25 (42.4) | 30 (50.8) | 29 (49.2) | |||
| Splenomegaly | |||||||||
| Present | 21 (58.3) | 15 (41.7) | 0.291 | 20 (55.6) | 16 (44.4) | 0.373 | 22 (61.1) | 14 (38.9) | 0.555 |
| Absent | 32 (69.6) | 14 (30.4) | 30 (65.2) | 16 (34.8) | 31 (67.4) | 15 (32.6) | |||
| Stage | |||||||||
| I–II | 14 (53.8) | 12 (46.2) | 0.164 | 12 (46.2) | 14 (53.8) | 0.061 | 9 (34.6) | 17 (65.4) | 0.005a |
| III–IV | 39 (69.6) | 17 (30.4) | 38 (67.9) | 18 (32.1) | 38 (67.9) | 18 (32.1) | |||
| IPI | |||||||||
| 0–2 | 27 (60.0) | 18 (40.0) | 0.333 | 23 (51.1) | 22 (48.9) | 0.043 | 21 (46.7) | 24 (53.3) | 0.032b |
| 3–5 | 26 (70.3) | 11 (29.7) | 27 (73.0) | 10 (27.0) | 26 (70.3) | 11 (29.7) | |||
| B2M | |||||||||
| >Upper limit of normal | 35 (76.1) | 11 (23.9) | 0.014b | 32 (69.6) | 14 (30.4) | 0.071 | 31 (67.4) | 15 (32.6) | 0.037b |
| Normal | 18 (50.0) | 18 (50.0) | 18 (50.0) | 18 (50.0) | 16 (44.4) | 20 (55.6) | |||
| LDH | |||||||||
| >Upper limit of normal | 40 (72.7) | 15 (27.3) | 0.029b | 30 (61.2) | 19 (38.8) | 0.813 | 34 (61.8) | 21 (38.2) | 0.240 |
| Normal | 13 (48.1) | 14 (51.9) | 14 (58.3) | 10 (41.7) | 13 (48.1) | 14 (51.9) | |||
| WBC | |||||||||
| >Upper limit of normal | 11 (44.0) | 14 (56.0) | 0.010b | 12 (48.0) | 13 (52.0) | 0.111 | 11 (44.0) | 14 (56.0) | 0.106 |
| Normal | 42 (73.7) | 15 (26.3) | 38 (66.7) | 19 (33.3) | 36 (63.2) | 21 (36.8) | |||
| Ki-67 | |||||||||
| ≥30% | 38 (71.7) | 15 (28.3) | 0.070 | 33 (62.3) | 20 (37.7) | 0.746 | 32 (60.4) | 21 (39.6) | 0.449 |
| <30% | 15 (51.7) | 14 (48.3) | 17 (58.6) | 12 (41.4) | 15 (51.7) | 14 (48.3) | |||
| Pathology | |||||||||
| PTCL-NOS | 26 (70.3) | 11 (29.7) | 0.440 | 22 (59.5) | 15 (40.5) | 0.212 | 26 (70.3) | 11 (29.7) | 0.962 |
| Other | 19 (79.2) | 5 (20.8) | 18 (75) | 6 (25) | 17 (70.8) | 7 (29.2) | |||
a
P<0.01
b
P<0.05. EZH2, enhancer of zeste homolog 2; HDAC, histone deacetylase; PTCL, peripheral T cell lymphoma; PTCL-NOS, PTCL not otherwise specified; IPI, international prognostic index; B2M, β2 microglobulin; LDH, lactate dehydrogenase; WBC, white blood count.